Frequently Asked Questions for RFA-RM-17-022, RFA-RM-17-023, RFA-RM-17-024, & RFA-RM-17-028
The following Frequently Asked Questions (FAQs) are for Use-Inspired Research to Optimize Adherence, Behavior Change Interventions, and Outcomes competing revision (R01, U01, R34) and exploratory/developmental (R21) funding opportunity announcements (RFA-RM-17-022, RFA-RM-17-023, RFA-RM-17-024, & RFA-RM-17-028). For additional background on the SOBC Research Network please see the original FAQs.
SOBC Measures Repository Questions
Competing Revision Questions
10. Is there a relative preference for studies that include experimental manipulation in a new arm versus studies that use multiple measures from the repository and statistical methods to uncover potentially multiple mechanisms?
11. Should the focus in R21 applications always on patient-oriented outcomes (e.g., medication adherence), or could the behavior change also be focused on provider behaviors (e.g., medication ordering behaviors)?
14. I noticed that the FOAs were advertised by NIDA and NCI. Is the R21 required to be fundable by NIDA or NCI or could it be targeted to another Institute or Center depending on the outcome of interest?
19. What types of activities are anticipated for these RFAs and are there any relative priorities? Specifically, is there priority for assay development and refinement versus target engagement studies versus broader longitudinal studies that include both demonstrations of target engagement and behavior change?
- Descriptive title of proposed activity
- Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
- Names of other key personnel
- Send it to Dr. Will M. Aklin (National Institute on Drug Abuse) at firstname.lastname@example.org.
The SOBC notion of targets should not be confused with the specific area of medical regimen adherence. Some specific examples of treatment/medical regimen adherence that might be an outcome include but are not limited to adherence to prevention or treatment protocols that have broad health implications across a wide range of functional and clinical outcomes and disease conditions. Specifically, adherence to prescriptions, screenings, immunizations, behavioral regimens, and the like, as prescribed by a health professional or as an evidence-based recommendation of an authorized entity, such the Centers for Disease Control and Prevention or the U.S. Preventive Services Task Force, is a highly-desired health behavior outcome.
This page last reviewed on November 8, 2017